In this study, we analyzed the actual clinical situation of cabozantinib as a second-line treatment after IO combination therapy using large-scale retrospective data from JUOG. Although this study included a large cohort and the treatment strategies slightly differed at each facility, it is meaningful to investigate the actual situation of second-line treatment after IO combination treatment in Japan in recent years. The purpose of this study was to clarify the utility of second-line cabozantinib treatment after IO combination therapy. The ORR for second-line cabozantinib after IO combination therapy was 32%, PFS was 10.5months, and OS was NR (6-month OS rate was 84%, 12-month OS rate was 71%). The factors significantly associated with efficacy were first-line treatment discontinuation because of PD and liver metastasis. None of the AEs significantly exceeded those previously reported. Sequential treatment remains important for metastatic RCC treatment. Third-line treatment after cabozantinib administration was associated with PFS and OS of 3.9 and 7.9months, respectively, indicating that efficacy can be expected after cabozantinib treatment.
Based on the results of the phase 3 METEOR trial8, we are using cabozantinib in clinical practice. Compared with everolimus, cabozantinib provided clear benefits for the primary endpoint of PFS and secondary endpoint of OS. The AEs of this drug were also manageable. However, in METEOR trial, approximately 5% of patient received IO before cabozantinib. It is unlikely that this situation reflects the efficacy of cabozantinib after IO administration.
The recently reported phase 3 CONTACT-03 trial evaluated the efficacy of cabozantinib in patients previously treated with IO10. This trial compared the efficacy of cabozantinib alone and in combination with atezolizumab. First, it should be noted that the cabozantinib monotherapy group had median PFS of 10.8months, in line with the current study results. The results support the efficacy of cabozantinib as sequential treatment in the IO era. Median OS was NR. The results of this phase 3 trial failed to demonstrate the efficacy of add-on atezolizumab. The BREAKPOINT trial, a phase 2 study in 31 cases has been reported. Median PFS was 8.3months, OS was 13.8months and ORR was 37.9%. Grade 34 adverse events occurred in 47%. Although this study involved a relatively small number of cases, it is a very important result when considering the theme of this paper9.
The After-IO trial was conducted as a follow-up study of a phase 3 trial of patients treated with nivolumab11. Axitinib and other TKIs have produced high response rates. However, information on cabozantinib was lacking in this study because of the timing of its approval. A report from the Italian Meet Uro 7 group provided real-world results for cabozantinib after IO monotherapy12. According to this study, cabozantinib was linked to longer PFS than everolimus and other TKIs. In addition, cabozantinib is the most frequently selected drug in clinical practice. Thus, the results of the Italian study do not reflect the efficacy of cabozantinib in clinical practice after IO combination therapy, which is currently the mainstream strategy.
The reason for first-line treatment discontinuation was an independent predictor of PFS in patients treated with cabozantinib. In patients who discontinued first-line therapy because of AEs, median PFS was not reached in the IO-IO or IO-TKI group. We believe that cabozantinib administration in a state of relatively high drug sensitivity led to good results. The time from first-line treatment to cabozantinib administration was not a significant predictor of PFS. In this regard, some patients are expected to be highly sensitive to drug therapy in general. Conversely, second-line treatment is not effective in some patients with rapid tumor growth and a short period between first- and second-line treatment. We anticipate that the efficacy of cabozantinib will be limited in some patients with accelerated tumor growth after PD. Median PFS did not reach 10months in patients who discontinued first-line treatment because of PD, highlighting the need for new systemic drugs.
Analyses have been conducted by metastatic organ in patients with RCC. Metastasis to the liver, bone, and brain is associated with poor prognoses. Xue et al. also found that liver metastases carried the worst prognosis13. In our study, the efficacy of cabozantinib in patients with bone and brain metastases was relatively satisfactory. Cabozantinib has inhibitory effects on MET and AXL, and it is expected to be effective against bone metastasis14. The METEOR trial also recorded a high response rate in patients with bone metastasis8. Cabozantinib exhibited considerable intracranial activity and an acceptable safety profile in patients with RCC and brain metastases15. In this study, we were unable to examine the details of local treatment of the brain. In addition, few cases of brain metastasis have been investigated, and further analysis is required. A certain effect has been demonstrated, as indicated by the results of this study. It is suggested that efficacy can be expected even after IO combination treatment in these metastatic organs. Meanwhile, the efficacy in patients with liver metastasis was limited. Liver metastases from RCC are reported to carry a poorer prognosis than liver metastases from other cancer types treated with IO16. Several reports discussed poor prognosis associated with liver metastases. James et al. found that the presence of liver metastasis significantly reduced tumor-specific immunity in an antigen-specific, PD-1-dependent manner. This process was associated with the coordinated activation of regulatory T cells and modulation of intratumoral CD11b+ monocytes17. The presence of liver metastasis was correlated with fewer CD8+ T cells at the invasive margin in distant tumors18. We expect new systemic treatments in the future for patients with liver metastasis.
The evaluation of AEs is expected to differ between retrospective studies and clinical trials. In addition, this study was based on multi-institutional data, and there are disparities in the awareness of AEs among institutions. The rate of all-grade AEs was somewhat low compared with the findings for cabozantinib in clinical trials8. This finding should not be interpreted as a low incidence of AEs in the Japanese population but rather as a limitation of information collection. However, the incidence of grade 3 or higher AEs was 28%, in line with prior findings8. These data serve as an index for Japanese data after IO combination treatment. No grade 5 AEs were observed in this population. It is considered that cabozantinib can be used safely in this population after molecular targeted therapy. A report found that Japanese patients are relatively prone to liver dysfunction19, and the present data recorded Grade 3 or higher liver dysfunction in six patients, which should be noted.
Expectations for sequential therapy might be lower than that in the previous age of molecular targeted drugs, but in real-world practice, sequential systemic therapy is often used to treat metastatic RCC. When performing sequential treatment, it is desirable to avoid the situation in which subsequent therapeutic effects are not anticipated. Cabozantinib is a relatively effective TKI, and the effects of subsequent systemic treatment after cabozantinib were analyzed in this study. Although PFS and OS were not substantially extended, a certain effect can be expected in patients who started third-line treatment. Luigi et al. summarized systemic treatment after cabozantinib in 56 patients. Median OS after cabozantinib was 7.7months, while median TTF after cabozantinib was 2.8months. However, only three of the participants in this study used IO combination as first-line treatment20. There are no large-scale reports of the use of cabozantinib after IO combination followed by systemic treatment. Of course, some patients receive best supportive care after cabozantinib administration, suggesting that AE management is possible.
Several combination treatments have been reported as second-line treatments after IO combination in recent years. One study verified the effect of adding atezolizumab to cabozantinib10. Unfortunately, no benefit was observed. Another phase 2 single-arm trial examined combination therapy with cabozantinib and belzutifan, in which PFS was 13.8months21. Although a simple comparison cannot be made, the addition of belzutifan could be promising given the PFS of approximately 10months in our study and the aforementioned CONTACT03 trial10. The phase 3 LITESPARK011 trial comparing cabozantinib with the combination of lenvatinib and belzutifan is currently underway7. The result of this study should be watched closely. It is hoped that the approval of these promising treatments will lead to improved prognoses in patients who discontinued IO combination therapy because of PD and patients with liver metastases, who had poor prognoses in this study.
This research had some limitations. First, this was a retrospective study. Treatment selection was left to the discretion of each facility, leading to varied treatments. In addition, this research used information from facilities such as university hospitals and cancer centers, and there is a possibility that the protocols of these situations slightly deviate from those used in hospitals throughout Japan. At the time of enrollment in this study, no patients in whom lenvatinib plus pembrolizumab was discontinued and cabozantinib was administered were included. In actual clinical practice, this strategy is frequently employed. New research is expected to clarify this issue in the future. We were not able to verify the effects of cabozantinib at different starting doses in this study. This is an issue that should be verified in future research. Phase II CaboPoint trial is now on-going22. It is hoped that the results will become clearer once the results of this trial are published.
In this study, we analyzed the real-world data of cabozantinib in Japan after IO combination therapy using the JUOG database. A relatively high response rate was obtained even after IO combination therapy, and AE management was possible. The results of this relatively large-scale study clarified the usefulness of cabozantinib and identified factors associated with poor efficacy, namely first-line treatment discontinuation because of PD and liver metastasis.
Originally posted here:
Efficacy and safety of second-line cabozantinib after immuno ... - Nature.com
- Podcast 9 Athens part 3 and news - November 8th, 2009 [November 8th, 2009]
- Podcast 10 Athens part 4 - November 8th, 2009 [November 8th, 2009]
- Podcast 11 Athens Part 5 - November 8th, 2009 [November 8th, 2009]
- Episode 12 Cardiac Nuclear Medicine in the UK - November 8th, 2009 [November 8th, 2009]
- Podcast 13 Choline PET and prostate cancer - November 8th, 2009 [November 8th, 2009]
- Episode14 ED function and Dysponea - November 8th, 2009 [November 8th, 2009]
- ep 15 Collimator Choice and Reconstruction algorithm - November 8th, 2009 [November 8th, 2009]
- Episode 16 Dr Strauss on vulnerable plaque - November 8th, 2009 [November 8th, 2009]
- Episode17 Chemical Stress - November 8th, 2009 [November 8th, 2009]
- Episode 18 Myocardial Perfusion Imaging and Diabetes - November 8th, 2009 [November 8th, 2009]
- Episode 19 The INSPIRE trial - November 8th, 2009 [November 8th, 2009]
- 20 Dual isotope with a difference - November 8th, 2009 [November 8th, 2009]
- Episode 21 The real effect of stress - November 8th, 2009 [November 8th, 2009]
- Episode 22 D-SPECT - November 8th, 2009 [November 8th, 2009]
- Episode 23 VQ Reprise - November 8th, 2009 [November 8th, 2009]
- Episode 24 Hepatobiliary Nuclear Medicine - November 8th, 2009 [November 8th, 2009]
- Episode 25 Sleep Apnea - November 8th, 2009 [November 8th, 2009]
- Episode 26 Imaging Post Traumatic Stress Disorder - November 8th, 2009 [November 8th, 2009]
- Episode 27 Cardiac Stem Cells - November 8th, 2009 [November 8th, 2009]
- Episode 28 Molly Supply - November 8th, 2009 [November 8th, 2009]
- Episode 29 Melanoma therapy interview with Dr Ekaterina Dadachova - November 8th, 2009 [November 8th, 2009]
- Episode 30 Viral Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 31 breast radiotherapy using radioisotopes - November 8th, 2009 [November 8th, 2009]
- Episode 32 news from snm - November 8th, 2009 [November 8th, 2009]
- Episode 33 EBV Imaging and Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 34 Dr Lele SNM India 2009 - December 14th, 2009 [December 14th, 2009]
- Episode 35 Dr Andrew Scott from the Ludwig institute - January 10th, 2010 [January 10th, 2010]
- Episode 36 CardiArc - February 25th, 2010 [February 25th, 2010]
- Episode 37 Dr Modder Radiosynoviorthesis (Radiation Synovectomy) - March 31st, 2010 [March 31st, 2010]
- Episode 38 Indian Nuclear Medicine With Dr Malhotra and Dr Krishna - May 28th, 2010 [May 28th, 2010]
- Episode 39 Prof Ora Israel The Utility of Hybrid Imaging - July 13th, 2010 [July 13th, 2010]
- Episode 40 New V/Q SPECT developments - October 11th, 2010 [October 11th, 2010]
- Episode 41 scintimun - February 14th, 2011 [February 14th, 2011]
- Episode 42 Radio-Isotope Supply into the future - March 6th, 2011 [March 6th, 2011]
- Podcast 4: DNA therapy - April 24th, 2011 [April 24th, 2011]
- Sorry about the delay a new podcast will be out soon! - April 24th, 2011 [April 24th, 2011]
- Podcast 5 Flash 3D - April 24th, 2011 [April 24th, 2011]
- Podcast 6 Affibody - April 24th, 2011 [April 24th, 2011]
- Podcast 7 EANM 2006 Athens Part 1 - April 24th, 2011 [April 24th, 2011]
- Podcast 8 Athens Part 2 - April 24th, 2011 [April 24th, 2011]
- Episode 43 Rapidscan Part 1, 720P high quality video version - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Ipod quality video - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Audio version - May 1st, 2011 [May 1st, 2011]
- Episode 45 Mummies with cardiovascular disease video - May 21st, 2011 [May 21st, 2011]
- Episode 45 Mummies with cardiovascular disease audio edition - May 21st, 2011 [May 21st, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective - August 7th, 2011 [August 7th, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective audio version - August 7th, 2011 [August 7th, 2011]
- Episode 47 Cardiac Image Fusion With Dr Kaufmann - September 18th, 2011 [September 18th, 2011]
- Episode 47 Cardiac Fusion with Dr Kaufmann video version - September 18th, 2011 [September 18th, 2011]
- Dear Steve, I am and many more like me are your one more thing. - October 9th, 2011 [October 9th, 2011]
- EPISODE 48 PET MRI camera from Siemens with Dr Georgi audio - October 23rd, 2011 [October 23rd, 2011]
- EPISODE 48 PET MRI camera from Siemens Dr Georgi video - October 23rd, 2011 [October 23rd, 2011]
- Silicon Biosystems to Present Single-Circulating Tumor Cell Molecular Characterization at the Fourth World CTC Summit - April 25th, 2012 [April 25th, 2012]
- Leukaemia cells have a remembrance of things past - April 25th, 2012 [April 25th, 2012]
- Technologist Education Requirements Can Help Cut Repeat Scans - April 25th, 2012 [April 25th, 2012]
- HKU Collaborative Research Discovers A Novel Molecular Mechanism Of A New Anti-HIV-1 Drug Candidate - April 25th, 2012 [April 25th, 2012]
- Focal Segmental Glomerulosclerosis and the Nephrotic Syndrome - Part 1 Clinical - Video - May 4th, 2012 [May 4th, 2012]
- Electro-Medicine : Biological Physics - The Molecular Basis of Alzheimers Disease - Video - May 4th, 2012 [May 4th, 2012]
- osdd heterocyclic compounds and molecular medicines - Video - May 4th, 2012 [May 4th, 2012]
- Molecule to Medicine: The Biomarker Frontier - Video - May 4th, 2012 [May 4th, 2012]
- Fulfilling the Promise of Molecular Medicine in a Developmental Brain Disorder - Video - May 4th, 2012 [May 4th, 2012]
- Focus on Stefanie Dimmeler - Video - May 4th, 2012 [May 4th, 2012]
- Dundee - May 4th, 2012 [May 4th, 2012]
- Nanotechnology In Medicine: Huge Potential, But What Are The Risks? - May 5th, 2012 [May 5th, 2012]
- Cutting Edge Technology Coming To DMH - May 5th, 2012 [May 5th, 2012]
- This Week in Experimental and Molecular Pathology - May 5th, 2012 [May 5th, 2012]
- Researchers' discovery offers hope for cancer, heart disease miracle drugs - May 7th, 2012 [May 7th, 2012]
- Penn State student Zachary Hostetler from Garnet Valley is being honored as a student marshal - May 7th, 2012 [May 7th, 2012]
- NCKU Student Wins Prestigious Award for Anti-Cancer Research - May 10th, 2012 [May 10th, 2012]
- In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers ... - May 10th, 2012 [May 10th, 2012]
- Pitt team uses genomics to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- Genomics used to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- 2 molecular biologists get $500K medical prize - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists share $500K medical prize - May 13th, 2012 [May 13th, 2012]
- Lab21 Unveils New Molecular Analysis Services at Greenville Site - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists from NYC to share $500K medical prize for pioneering research on cells - May 13th, 2012 [May 13th, 2012]
- Two Molecular Biologists Get $500K Medical Prize - May 13th, 2012 [May 13th, 2012]
- Pair of molecular biologists receive Albany Medical Center Prize - May 13th, 2012 [May 13th, 2012]
- CNIO scientists successfully test the first gene therapy against aging-associated decline - May 16th, 2012 [May 16th, 2012]
- Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine' - May 16th, 2012 [May 16th, 2012]